HealthLinx scores high with OvPlex
Monday, 08 December, 2008
Diagnostics company HealthLinx has reported increased efficiency of its ovarian cancer diagnostic OvPlex in a Phase II biomarker trial.
The trial showed a diagnostic efficiency of 98 per cent in the second-generation test. The first generation diagnostic, distributed by ARL Pathology, has an efficiency of 93 per cent.
The trial was aimed at testing the efficiency of the two new biomarkers added to the OvPlex panel, HTX005 and HTX010. The panel includes the gold standard CA125 biomarker.
The study used 107 samples, including 46 disease subjects and 61 controls. The company now intends to run a larger Phase II trial involving 350 disease samples plus controls across multiple sites, including Asia and Europe.
The second-generation test is expected to be ready late next year or in early 2010.
Antimicrobial resistance in children rises globally — 100K+ samples reveal
Spanning 82 countries, there was an increase in every region between 2004 and 2022, with the...
Robotic laboratory to fast-track drug invention, trials and commercialisation
The lab will house an automated system for high-throughput X-ray crystallography, often referred...
Bio-inspired robotic bird has stable flight in its sights
The nankeen kestrel is among the most stable fliers in the avian world. Using motion capture...
